Endometrial pathologies associated with postmenopausal tamoxifen treatment (Q35857222)

10 August 2017

1 reference

title

Endometrial pathologies associated with postmenopausal tamoxifen treatment (English)

1 reference

10 August 2017

1 reference

Ilan Cohen

1

1 reference

PubMed ID

15297160

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

94

1 reference

10 August 2017

2

1 reference

10 August 2017

256-266

1 reference

Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial lesions in patients undergoing tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

The effect of tamoxifen on the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Pathology of endometrium treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen and the endometrium: findings of pelvic ultrasound examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Transvaginal endometrial sonography in postmenopausal women taking tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen and endometrial pathologies: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Uterine side effects of tamoxifen: a need for systematic pretreatment screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Hysteroscopic evaluation of the endometrium of post-menopausal patients with breast cancer before and after tamoxifen use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Longitudinal hysteroscopic follow-up during tamoxifen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial lesions after tamoxifen therapy in breast cancer women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Risk of endometrial cancer after tamoxifen treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen and risk of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial cancer in polyps associated with tamoxifen use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

A retrospective study of tamoxifen and endometrial cancer in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Second cancers after adjuvant tamoxifen therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen therapy for breast cancer and endometrial cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Association between endometrial cancer and tamoxifen treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen and risk of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Uterine carcinosarcoma in association with tamoxifen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Multiple primary cancers of the breast, endometrium and ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Association of tamoxifen and uterine sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Tamoxifen-induced uterine abnormalities: the role of imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Surveillance for endometrial cancer in women receiving tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.03.048

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.03.048

1 reference

10 August 2017

1 reference

PubMed ID

15297160